“Axovant Sciences’ ( AXON ) investigational drug Nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia has failed in a phase II trial, sending the shares down over 27%.”
Read the Full Story at nasdaq.com
AXON Throws In The Towel On Nelotanserin, MNLO On Watch, VYGR Sails Ahead | NASDAQ
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ